FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

hours per response

OMB Number: 3235-0287
Estimated average burden

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* KIDRON NADAV					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				- 1	ORMP]							X	Director		X	10% Ow	ner	
(Last)	(F	First)	(Middle)	$-\lfloor$	Ordivi	.]						X	Officer (g below)	ive title		Other (s below)	pecify	
142 W. 57TH ST.					3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019							President and CEO						
(Street)	ORK N	ĮΥ	10019		4. If Amendment, Date of Original Filed (Month/Day/Year)							- 1	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(City)	(2)	State)	(Zip)										Form filed by More than One Reporting Person					
		٦	Гable I - Non-	Deriva	tive S	Securiti	es Acq	uired, Di	spc	osed of,	or Bene	eficially (Owned					
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			(A) or 3, 4 and 5)	and 5) Securities Beneficially Owned Followi		6. Owr Form: (D) or (I) (Ins	Direct I Indirect E tr. 4)	7. Nature of Indirect Beneficial Ownership				
							Code V	ı	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		re s I (A) or d of (D)	6. Date Exercisable and Expiration Date (Month/Day/Year) Underlying Derivative Sec (Instr. 3 and 4)			es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)				
Stock Option (right to buy)	\$3.16	02/26/2019		D ⁽¹⁾			196,500	(1)	0:	12/26/2029	Common Stock	196,500	\$0	0		D		
Stock Option (right to buy)	\$3.16	09/12/2019		A ⁽¹⁾		196,500		(1)	0	9/12/2029	Common Stock	196,500	\$0	196,5	00	D		

Explanation of Responses:

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

/s/ Nadav Kidron

09/12/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.